Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Summary
To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate to Severe Central Neuropathic Pain in China
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
408
Start Date
2024-05-30
Completion Date
2027-08-07
Last Updated
2024-05-20
Healthy Volunteers
No
Conditions
Interventions
HSK16149 20mg-40mg BID
Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
Placebo
Placebo, oral, 2 capsules twice daily